Context. “Compound 23” (LEO Pharma) is an oral IL-17A protein−protein interaction modulator being developed for psoriasis and other inflammatory diseases . Like most cytokines, the involvement of IL-17A in chronic inflammatory diseases has been well-researched . IL-17A is the key cytokine that mediates psoriasis , and targeting it or its [...]
5 minute read
Jul. 27, 2022
“Compound 23” (LEO Pharma) is an Oral IL-17A Protein−Protein Interaction Modulator
compound 23
oral interleukin 17A modulator favorable in vivo PK profile in multiple species from a previous patent and SBDD J. Med. Chem. LEO Pharma Research & Early Development, Ballerup, DK
Loading...
